Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

Adjuvant pembrolizumab improved recurrence-free survival among patients with resected Merkel cell carcinoma, but not significantly.

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or ...

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...